Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Geographic Atrophy Secondary to Age-related Macular Degeneration: early-phase trial registry
5 of 5 indexed Geographic Atrophy Secondary to Age-related Macular Degeneration trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Geographic Atrophy Secondary to Age-related Macular Degeneration: 5 US clinical trials tracked, 5 recruiting.
Geographic Atrophy Secondary to Age-related Macular Degeneration is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Complement Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition geographic-atrophy-secondary-to-age-related-macular-degeneration
OPEN 5 | RECR 100% | LATE 0 | EARLY 4 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Geographic Atrophy Secondary to Age-related Macular Degeneration lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Geographic Atrophy Secondary to Age-related Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Geographic Atrophy Secondary to Age-related Macular Degeneration is recruiting above its size-band peers.
5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Geographic Atrophy Secondary to Age-related Macular Degeneration research.
Complement Therapeutics accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Geographic Atrophy Secondary to Age-related Macular Degeneration enrolment sits around 240 participants.
Median target enrolment is 240 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Geographic Atrophy Secondary to Age-related Macular Degeneration research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
NCT07441642
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Apellis Pharmaceuticals
NCT07215390
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
ADARx Pharmaceuticals
NCT06990269
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
Complement Therapeutics
NCT07392255
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
Complement Therapeutics
NCT07144137
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Geographic Atrophy Secondary to Age-related Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Geographic Atrophy Secondary to Age-related Macular Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Geographic Atrophy Secondary to Age-related Macular Degeneration page
5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Geographic Atrophy Secondary to Age-related Macular Degeneration trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Complement Therapeutics sponsors the most Geographic Atrophy Secondary to Age-related Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See Complement Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Geographic Atrophy Secondary to Age-related Macular Degeneration condition card totals 5 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.